Multiplatform tear proteomic profiling reveals novel non-invasive biomarkers for diabetic retinopathy

Fan，Zixin1,2; Hu，Yarou1; Chen，Laijiao1; Lu，Xiaofeng1; Zheng，Lei1; Ma，Dahui1; Li，Zhiqiang3; Zhong，Jingwen3; Lin，Lin4; Zhang，Sifan5; Zhang，Guoming1

2024

10.1038/s41433-024-02938-0

Eye (Basingstoke)   影响因子和分区

0950-222X

1476-5454

Objectives: To investigate a comprehensive proteomic profile of the tear fluid in patients with diabetic retinopathy (DR) and further define non-invasive biomarkers. Methods: A cross-sectional, multicentre study that includes 46 patients with DR, 28 patients with diabetes mellitus (DM), and 30 healthy controls (HC). Tear samples were collected with Schirmer strips. As for the discovery set, data-independent acquisition mass spectrometry was used to characterize the tear proteomic profile. Differentially expressed proteins between groups were identified, with gene ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes enrichment analysis further developed. Classifying performance of biomarkers for distinguishing DR from DM was compared by the combination of three machine-learning algorithms. The selected biomarker panel was tested in the validation cohort using parallel reaction monitoring mass spectrometry. Results: Among 3364 proteins quantified, 235 and 88 differentially expressed proteins were identified for DR when compared to HC and DM, respectively, which were fundamentally related to retina homeostasis, inflammation and immunity, oxidative stress, angiogenesis and coagulation, metabolism, and cellular adhesion processes. The biomarker panel consisting of NAD-dependent protein deacetylase sirtuin-2 (SIR2), amine oxidase [flavin-containing] B (AOFB), and U8 snoRNA-decapping enzyme (NUD16) exhibited the best diagnostic performance in discriminating DR from DM, with AUCs of 0.933 and 0.881 in the discovery and validation set, respectively. Conclusions: Tear protein dysregulation is comprehensively revealed to be associated with DR onset. The combination of tear SIR2, AOFB, and NUD16 can be a novel potential approach for non-invasive detection or pre-screening of DR. Clinical trial registration: Chinese Clinical Trial Registry Identifier: ChiCTR2100054263. https://www.chictr.org.cn/showproj.html?proj=143177. Date of registration: 2021/12/12.

SCI

英语

其他

CLINICAL MEDICINE

2-s2.0-85184496415

Scopus

1.Shenzhen Eye Hospital,Jinan University,Shenzhen Eye Institute,Shenzhen,Guangdong,518040,China
2.International Graduate School at Shenzhen,Tsinghua University,Shenzhen,Guangdong,518040,China
3.Shenmei Eye Hospital,Meizhou,Guangdong,514000,China
4.Southern University of Science and Technology,Shenzhen,Guangdong,518040,China
5.New York University,New York,10003,United States

Fan，Zixin,Hu，Yarou,Chen，Laijiao,et al. Multiplatform tear proteomic profiling reveals novel non-invasive biomarkers for diabetic retinopathy[J]. Eye (Basingstoke),2024.

Fan，Zixin.,Hu，Yarou.,Chen，Laijiao.,Lu，Xiaofeng.,Zheng，Lei.,...&Zhang，Guoming.(2024).Multiplatform tear proteomic profiling reveals novel non-invasive biomarkers for diabetic retinopathy.Eye (Basingstoke).

Fan，Zixin,et al."Multiplatform tear proteomic profiling reveals novel non-invasive biomarkers for diabetic retinopathy".Eye (Basingstoke) (2024).